This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Laskey, W. K. Articles by Beach, D. Search for Related Content PubMed PubMed Citation Articles by Laskey, W. K. Articles by Beach, D.

CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY

Frequency and clinical significance of ischemic preconditioning during percutaneous coronary intervention

^* Division of Cardiology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA

^* Reprint requests and correspondence: Dr. Warren K. Laskey, Cardiac Catheterization Laboratory, National Naval Medical Center, 8901 Wisconsin Avenue, Bethesda, Maryland 20889, USA.
warrenlaskey{at}earthlink.net

OBJECTIVES: We sought to examine the short- and long-term clinical consequences of ischemic preconditioning (IP) during percutaneous coronary intervention (PCI).

BACKGROUND: Ischemic preconditioning has been demonstrated in animal models to significantly diminish the extent of myocardial necrosis consequent to coronary occlusion. Surrogate markers of ischemic injury (ST segment shift, lactate release, creatine kinase release) in humans have been shown to be similarly diminished with IP elicited during PCI. There are no studies of the frequency of inducibility of IP during PCI, nor are there longer-term data on the clinical relevance of IP.

METHODS: A total of 382 patients underwent elective PCI employing a previously validated protocol to elicit IP. Procedural, in-hospital, and one-year outcomes were recorded.

RESULTS: Ischemic preconditioning was elicited in 80% of patients and was associated with a significant reduction in the likelihood of in-hospital adverse cardiac events (IP group, 12.1%; non-IP group, 44.1%; p < 0.0001). Women and diabetic patients were less likely to exhibit IP. By one year, patients failing to manifest IP were at significantly greater risk of post-discharge death or non-fatal myocardial infarction (MI) (non-IP group, 25.9%; IP group, 11.1%; p < 0.002). Failure to manifest IP was significantly and independently associated with an increased risk of death or non-fatal MI by one year.

CONCLUSIONS: Clinically relevant short- and long-term cardioprotection can be found in association with IP during PCI. In-hospital adverse ischemic events are significantly diminished in patients with IP, as are the risks of death or non-fatal MI at one year. Failure to elicit IP during PCI serves as an independent marker of increased risk of future ischemic events.

Abbreviations and Acronyms   AE = adverse clinical event   CI = confidence interval   CK-MB = creatine phosphokinase-MB fraction   ECG = electrocardiogram/electrocardiograph(ic)   IP = ischemic preconditioning   MI = myocardial infarction   PCI = percutaneous coronary intervention

This article has been cited by other articles:

				J. Huffmyer and J. Raphael Physiology and Pharmacology of Myocardial Preconditioning and Postconditioning Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2009; 13(1): 5 - 18. [Abstract] [PDF]

				L. Wang, N. Oka, M. Tropak, J. Callahan, J. Lee, G. Wilson, A. Redington, and C. A. Caldarone Remote ischemic preconditioning elaborates a transferable blood-borne effector that protects mitochondrial structure and function and preserves myocardial performance after neonatal cardioplegic arrest. J. Thorac. Cardiovasc. Surg., August 1, 2008; 136(2): 335 - 342. [Abstract] [Full Text] [PDF]

				G. Niccoli, L. Altamura, A. Fabretti, G. A. Lanza, L. M. Biasucci, A. G. Rebuzzi, A. M. Leone, I. Porto, F. Burzotta, C. Trani, et al. Ethanol Abolishes Ischemic Preconditioning in Humans J. Am. Coll. Cardiol., January 22, 2008; 51(3): 271 - 275. [Abstract] [Full Text] [PDF]

				R. M. Mentzer Jr, M. S. Jahania, and R. D. Lasley Myocardial Protection Card. Surg. Adult, January 1, 2008; 3(2008): 443 - 464. [Full Text]

				E K Iliodromitis, S Kyrzopoulos, I A Paraskevaidis, K G Kolocassides, S Adamopoulos, G Karavolias, and D T Kremastinos Increased C reactive protein and cardiac enzyme levels after coronary stent implantation. Is there protection by remote ischaemic preconditioning? Heart, December 1, 2006; 92(12): 1821 - 1826. [Abstract] [Full Text] [PDF]

				M. M.H. Cheung, R. K. Kharbanda, I. E. Konstantinov, M. Shimizu, H. Frndova, J. Li, H. M. Holtby, P. N. Cox, J. F. Smallhorn, G. S. Van Arsdell, et al. Randomized Controlled Trial of the Effects of Remote Ischemic Preconditioning on Children Undergoing Cardiac Surgery: First Clinical Application in Humans J. Am. Coll. Cardiol., June 6, 2006; 47(11): 2277 - 2282. [Abstract] [Full Text] [PDF]

				I. Ungi, T. Ungi, Z. Ruzsa, E. Nagy, Z. Zimmermann, T. Csont, and P. Ferdinandy Hypercholesterolemia Attenuates the Anti-ischemic Effect of Preconditioning During Coronary Angioplasty Chest, September 1, 2005; 128(3): 1623 - 1628. [Abstract] [Full Text] [PDF]

				S. G. De Hert, F. Turani, S. Mathur, and D. F. Stowe Cardioprotection with Volatile Anesthetics: Mechanisms and Clinical Implications Anesth. Analg., June 1, 2005; 100(6): 1584 - 1593. [Abstract] [Full Text] [PDF]

				C. Garcia, K. Julier, L. Bestmann, A. Zollinger, L. K. von Segesser, T. Pasch, D. R. Spahn, and M. Zaugg Preconditioning with sevoflurane decreases PECAM-1 expression and improves one-year cardiovascular outcome in coronary artery bypass graft surgery Br. J. Anaesth., February 1, 2005; 94(2): 159 - 165. [Abstract] [Full Text] [PDF]

				M E Faircloth, S R Redwood, and M S Marber Ischaemic preconditioning and myocardial adaptation to serial intracoronary balloon inflation: cut from the same cloth? Heart, April 1, 2004; 90(4): 358 - 360. [Abstract] [Full Text] [PDF]